Theriva Biologics, Inc. (TOVX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Theriva Biologics, Inc. on October 29, 2025. The filing relates to the Company's capital raising activities under an existing "at-the-market" (ATM) sales agreement.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed is the authorization to sell up to $2,894,225 of common stock under the updated prospectus supplement.
Material Changes and Events
- Prospectus Supplement Filed: On October 29, 2025, the Company filed a prospectus supplement to its effective Form S-3 Registration Statement (File No. 333-279077).
- Sales Agreement: The offering is conducted pursuant to an Amended and Restated At Market Issuance Sales Agreement with A.G.P./Alliance Global Partners (the "Sales Agent").
- Commission Structure: The Sales Agent is entitled to a commission of up to 3.0% of the gross sales price per share sold.
- Sales Method: Sales will be made via "at the market offerings" as defined in Rule 415(a)(4). The Sales Agent is not obligated to sell a specific amount but will use commercially reasonable efforts.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or specific risk factors beyond standard securities law disclaimers. The document notes that the report does not constitute an offer to sell securities in any state where such an offer would be unlawful prior to registration.
Investor Verification Checklist
- Verify the current market price of TOVX common stock to estimate the potential share dilution from the $2,894,225 offering cap.
- Review the Company's most recent 10-K or 10-Q filings for actual cash position and burn rate, as this 8-K does not contain liquidity data.
- Confirm the status of the underlying Form S-3 Registration Statement (File No. 333-279077) to ensure it remains effective.
- Monitor future 8-K filings for actual sales volumes and proceeds received under this ATM agreement.